Atara Biotherapeutics to Participate in Cell Therapy Panel Discussion at the Cowen 43rd Annual Health Care Conference
March 01 2023 - 4:01PM
Business Wire
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell
immunotherapy, leveraging its novel allogeneic Epstein-Barr virus
(EBV) T-cell platform to develop transformative therapies for
patients with cancer and autoimmune diseases, today announced that
Pascal Touchon, President and Chief Executive Officer, will
participate in a cell therapy panel discussion at the Cowen 43rd
Annual Health Care Conference on Wednesday, March 8, 2023 at 11:10
a.m. PST / 2:10 p.m. EST.
A live webcast of the presentation will be available by visiting
the Investors and Media section of atarabio.com. An archived replay
of the webcast will be available on the Company's website for 30
days following the live presentation.
About Atara Biotherapeutics, Inc. Atara Biotherapeutics,
Inc. (@Atarabio) is a pioneer in T-cell immunotherapy leveraging
its novel allogeneic EBV T-cell platform to develop transformative
therapies for patients with serious diseases including solid
tumors, hematologic cancers and autoimmune disease. With our lead
program receiving marketing authorization in Europe, Atara is the
most advanced allogeneic T-cell immunotherapy company and intends
to rapidly deliver off-the-shelf treatments to patients with high
unmet medical need. Our platform leverages the unique biology of
EBV T cells and has the capability to treat a wide range of
EBV-associated diseases, or other serious diseases through
incorporation of engineered CARs (chimeric antigen receptors) or
TCRs (T-cell receptors). Atara is applying this one platform, which
does not require TCR or HLA gene editing, to create a robust
pipeline including: tab-cel for Epstein-Barr virus positive
post-transplant lymphoproliferative disease (EBV+ PTLD) and other
EBV-driven diseases; ATA188, a T-cell immunotherapy targeting EBV
antigens as a potential treatment for multiple sclerosis; and
multiple next-generation chimeric antigen receptor T-cell (CAR-T)
immunotherapies for both solid tumors and hematologic malignancies.
Improving patients’ lives is our mission and we will never stop
working to bring transformative therapies to those in need. Atara
is headquartered in Southern California. For additional information
about the company, please visit atarabio.com and follow us on
Twitter and LinkedIn.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230227005833/en/
INVESTORS & MEDIA: Investors Eric Hyllengren
805-395-9669 ehyllengren@atarabio.com
Media Alex Chapman 805-456-4772 achapman@atarabio.com
Atara Biotherapeutics (NASDAQ:ATRA)
Historical Stock Chart
From Jun 2024 to Jul 2024
Atara Biotherapeutics (NASDAQ:ATRA)
Historical Stock Chart
From Jul 2023 to Jul 2024